Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study

Phase 2negativerepeat-dose anxiety nasal sprayNegative

AI Analysis

Summary

Vistagen's repeat-dose anxiety nasal spray failed to demonstrate statistical superiority over placebo in a Phase 2 study. The company plans to meet with the FDA to determine the path forward for the drug candidate.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Failed to beat placebo in Phase 2 study

Importance:6/10

Sentiment:

-0.80

clinical trial failurePhase 2nasal sprayanxietyplacebo control

Related Companies

$VTGN

Read the original article

Published by BioSpace on August 7, 2026 12:09 PM

Read Original